Results 151 to 160 of about 39,781 (168)

Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: a prospective study from the RESPOND cohort consortium [PDF]

Clinical Infectious Diseases
BACKGROUND With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases associated with higher diabetes mellitus (DM) risk, this study explored the relationship between INSTI/non-INSTI regimens,
Dhanushi Rupasinghe, Ferdinand Wnm Wit, Lauren Greenberg   +2 more
exaly   +3 more sources

Field performance of the INSTI HIV-1/-2 antibody test in two South African antenatal clinics [PDF]

Journal of Medical Virology, 2019
This was a prospective study that assessed field performance of the INSTI HIV‐1/‐2 antibody test (INSTI test) in two antenatal clinics in South Africa (SA).
Thomas C. Quinn, Anton Stoltz, Simnikiwe H Mayaphi   +2 more
exaly   +2 more sources

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen

International Journal of Antimicrobial Agents, 2020
The aim of this study was to characterize the genotypic and phenotypic resistance profile to the integrase strand transfer inhibitor (INSTI) bictegravir (BIC) and other INSTIs in patients who previously failed twice-daily raltegravir (RAL)-based or twice-
Laura Galli, Maurizio Zazzi, Andrea Poli
exaly   +2 more sources

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting

Journal of Antimicrobial Chemotherapy
Background: Virological failures of first-line second-generation (SG) INSTI-based regimens are rare, usually characterized by low viremia and absence of drug resistance mutations.
Camilla Muccini, Nicola Gianotti, Vincenzo Spagnuolo   +2 more
exaly   +2 more sources

Trends in Serum Amylase Levels in People Living with HIV: A Comparison Between INSTI and NNRTI/PI-Based Regimens

Viruses
Background: Antiretroviral therapy (ART) has transformed HIV into a chronic manageable condition, yet metabolic toxicities including pancreatic enzyme alterations remain concerns.
keren Mahlab-Guri, Haitham Abu khadija, Daniel Elbirt   +2 more
exaly   +2 more sources

Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohort

HIV Medicine
RATIONALE: Doravirine (DOR) is an attractive new option both for ART-naïve people with HIV (PWH) and those with suppressed HIV-RNA who seek treatment simplification.
Alessandro Tavelli, Stefano Rusconi, Massimiliano Fabbiani   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

INSTI-Based Initial Antiretroviral Therapy in Adults with HIV, the HIV Outpatient Study, 2007–2018

AIDS Research and Human Retroviruses, 2021
Kate Buchacz, Frank J. Palella, Stockton Mayer   +2 more
exaly  

The Emergence of Resistance Under Firstline INSTI Regimens

Infection and Drug Resistance, 2022
Jiegang Huang, Fang Lu, Zhiman Xie
exaly  

Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy.

Open Forum Infectious Diseases, 2019
Mar Masiá, Marta Fernández-González, José A García   +2 more
exaly  

Performance evaluation of the point-of-care INSTI™ HIV-1/2 antibody test in early and established HIV infections

Journal of Clinical Virology, 2017
Laura G Wesolowski, Silvina Masciotra, Philip J Peters   +2 more
exaly